Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: Baseline for monitoring the effects of immunisation

Journal of Clinical Pathology

Volumn 68, Issue 2, 2015, Pages 135-140

  Mesher, David ^a   Cuschieri, Kate ^b   Hibbitts, Sam ^c   Jamison, Jackie ^d   Sargent, Alex ^a   Pollock, Kevin G ^e   Powell, Ned ^c   Wilson, Robbie ^d   McCall, Fiona ^e   Fiander, Alison ^c   Soldan, Kate ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d ANTRIM AREA HOSPITAL   (United Kingdom)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE; WART VIRUS VACCINE;

ADULT; ARTICLE; FEMALE; GENOTYPE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNIZATION; IRELAND; MAJOR CLINICAL STUDY; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; TUMOR INVASION; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADOLESCENT; AGE; AGE DISTRIBUTION; AGED; CANCER GRADING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; CLINICAL TRIAL; GENETICS; GREAT BRITAIN; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PHENOTYPE; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; GREAT BRITAIN; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNIZATION; IMMUNIZATION PROGRAMS; MIDDLE AGED; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHENOTYPE; PREVALENCE; STATE MEDICINE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84922193580     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202681     Document Type: Article

References (31)

1. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009;10:321-2.
2. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. IARC Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. 100B. Lyon, France: World Health Organisation International Agency for Research on Cancer, 2012.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
5. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16.
6. Smith JS, Linds L, Hoots B, et al. Human papilloma virus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
7. Howell-Jones R, Bailey A, Beddows S, et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010;103:209-16.
8. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
9. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-55.
10. Rowhani-Rahbar A, Alvarez FB, Bryan JT, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012;53:239-43.
11. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
12. Office for National Statistics (ONS). Cancer Registration Statistics, England, 2011. http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mb1-/no-42-2011/stb-cancer-statistics-registrations-2011.html (accessed Jul 2014).
13. ISD Scotland. Cancer Incidence 2011. http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp (accessed Jul 2014).
14. Welsh Cancer Intelligence and Surveillance Unit. Cancer Incidence 2011. http://www.wcisu.wales.nhs.uk/cancer-statistics (accessed Jul 2014).
15. The Northern Ireland Cancer Registry. Cancer Incidence 2011. http://www.qub.ac.uk/research-centres/nicr/CancerData/OnlineStatistics/Cervix/ (accessed Jul 2014).
16. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013;32:26-32.
17. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110:2804-11.
18. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
19. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
20. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011;7:1359-73.
21. Cuschieri K, Brewster DH, Williams AR, et al. Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 2010;102:930-2.
22. Powell NG, Hibbitts SJ, Boyde AM, et al. The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer 2011;128:1676-82.
23. Hibbitts S, Jones J, Powell N, et al. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 2008;99:1929-33.
24. Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006;95:52-61.
25. Powell N, Cuschieri K, Cubie H, et al. Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK). J Clin Virol 2013;58:571-4.
26. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis. Br J Cancer 2003;88:63-73.
27. Bogaards JA, Coupe VM, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011;22:505-15.
28. Public Health England. Annual HPV vaccine coverage in England: 2012/13. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/266190/HPV-AnnualDataTable2012-13-SHA-acc2.pdf (accessed Jul 2014).
29. Sinka K, Kavanagh K, Gordon R, et al. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 2014;68:57-63.
30. Public Health Wales. Vaccine Uptake in Children in Wales October to December 2013. http://www2.nphs.wales.nhs.uk:8080/VaccinationsImmunisationProgsDocs.nsf/($All)/A8D17455D972871580257C86004E0C38/$File/Cov13q4%20(Report109%20version1).pdf?OpenElement (accessed Sep 2014).
31. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30.